Biotech Sector Bounce Looks to Be Coming

The third quarter came to a close yesterday and it wasn’t a good one for the overall market, as the S&P 500 lost 6.94% for its worst quarterly performance in four years. Among the main sectors, the health care sector was the third-worst performer, with only energy and basic materials performing worse.biotech-etf
The recent selling in biotech and pharmaceutical stocks helped push the health care sector down as drug prices have become the latest hot-button debate for politicians. As a result of the public shaming, the iShares Biotechnology ETF (NASDAQ: IBB) over 13% last week, and it was down nearly 8% at its low this week before bouncing back.
I wrote an article on Sept. 22 stating that the slide in biotech sector stocks was likely to continue. It did. The IBB has fallen over 10% since that article was published, but now I think the selling is overdone and I look for the IBB to bounce back.
Looking at the same daily chart I used only nine days ago, you can see that the IBB had just hit its 50-day moving average and the trend line had been acting as support that I thought would turn into resistance. Well it did, but now there is a bigger, longer-term moving average that is coming into play.
IBB Daily Wyatt
When we look at the weekly chart – rather than use the one I used in the previous article – I updated and added the 104-week moving average. I had pointed out that the $275 level could act as support if the fund got down there. The IBB did dip below its 104-week briefly, but then it bounced.
Back in the summers of 2010 and 2011, the IBB experienced slight pullbacks, and in each case, the support of the 104-week moving average was the bottom for both pullbacks. During those two drawdowns was also the last time the 10-week RSI was as low as it is now.
IBB Weekly Wyatt
In addition to the support at the 104-week moving average and the oversold level being reached by the weekly RSI, there is another factor behind my thinking. When I ran my scans last night, there were a total of 128 bullish signals, which is the highest total since Aug. 25. Of the 128 total signals, 28 of them were in the health care sector and 15 of those stocks were either in the biotech sector or the pharma industry.
I looked at the daily and weekly charts for all of the biotech stocks and almost all of them have a similar pattern as the IBB. The 13-week moving average is still above the 52-week, and the 104-week is acting as support. I saw the same pattern over and over.
I would look to buy the IBB in the $300 to $310 range with a target of $350 in the short run and a long-term target of $400. I would use the 104-week moving average as a mental stop-loss point, only shutting the trade down if the IBB closes the week below the moving average.
Forget everything you thought you knew about the market
Because you’re about to discover a unique – and highly profitable – approach to stocks that maybe 1-in-1,000 investors know about. Yet it’s a simple, safe, and easy-to-use trading tactic that has, historically, made money nearly 90% of the time. Even better – following this simple strategy lets YOU determine how much money you make. Check it out now. Just click here. The next round of trades are all ready and waiting for you here.

To top